Patients with inoperable , advanced imatinib-resistant GIST were randomized ( @ : @ ) to receive masitinib ( @ mg/kg/day ) or sunitinib ( @ mg/day @-weeks-on/@-weeks-off ) until progression , intolerance , or refusal .